Anti-CRIP2 antibody

Anti-CRIP2 antibody

• DataSheet
• Material Safety Data Sheets (MSDS)

Mouse monoclonal to CRIP2

IHC-P

Human CRIP2

ESP1 antibody; Esp1 antibody; 0610010I23Rik antibody; AW743261 antibody; C77570 antibody; CRIP antibody; Crip2 antibody; CRIP2 antibody; CRP2 antibody; CRP2 antibody; CRP-2 antibody; CRP4 antibody; cysteine rich protein 2 antibody; Cysteine-rich intestinal protein antibody; cysteine-rich protein 2 antibody; ESP1 antibody; ESP1 antibody; heart LIM protein antibody; Hlp antibody; LIM domain protein ESP1/CRP2 antibody; LIM only protein HLP antibody; CRP antibody; CRIP antibody; CRP2 antibody; Crp antibody; Hlp antibody; CRP2 antibody; CRP4 antibody; C77570 antibody; AW743261 antibody; 0610010I23Rik antibody

Mouse IgG1

This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human CRIP2 (rh CRIP2; P52943; Met1-Pro208). The IgG fraction of the cell culture supernatant was purified by Protein A affinity chromatography.

Monoclonal

0.2 μm filtered solution in PBS with 5% trehalose

This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free.
Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.

CRIP2 is a putative transcription factor. It has a widespread tissue expression and is highly expressed in heart. CRIP2 contains two LIM zinc-binding domains. CRIP2 may participate in the differentiation of smooth muscle tissue. It also plays an important role in esophageal squamous cell carcinoma (ESCC) tumorigenesis. CRIP2 acts as a transcription repressor of the NF-κB-mediated proangiogenic cytokine expression and thus functionally inhibits tumor formation and angiogenesis. It interacts with the NF-κB/p65 to inhibit its DNA-binding ability to the promoter regions of the major proangiogenesis cytokines critical for tumor progression, including IL6, IL8, and VEGF. In conclusion, we provide compelling evidence that CRIP2 acts as a transcription repressor of the NF-κB-mediated proangiogenic cytokine expression and thus functionally inhibits tumor formation and angiogenesis.

• Chang DF. et al., 2003, Dev Cell. 4 (1):107-18.
• Huber A. et al., 2000, J Biol Chem. 275 (8): 5504-11.
• Karim MA. et al., 1996, Genomics. 31 (2): 167-76.